Brokerages Set Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Price Target at $43.40

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have received a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $43.40.

Several equities research analysts have recently commented on DMRA shares. Lifesci Capital raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, February 2nd. UBS Group started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. They issued a “buy” rating and a $45.00 target price for the company. Guggenheim reissued a “buy” rating and issued a $40.00 target price (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Royal Bank Of Canada started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They issued an “outperform” rating and a $40.00 target price for the company. Finally, Evercore started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 target price for the company.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $40,000. Geode Capital Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $266,000. Virtu Financial LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth $49,000. Sigma Planning Corp acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $334,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth $76,000. 14.20% of the stock is owned by institutional investors and hedge funds.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of DMRA opened at $25.30 on Monday. The stock has a fifty day moving average price of $25.19 and a two-hundred day moving average price of $24.66. Damora Therapeutics, Inc. Common Stock has a 52-week low of $2.45 and a 52-week high of $38.33. The company has a market cap of $1.56 billion, a price-to-earnings ratio of -4.53 and a beta of 1.50.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its earnings results on Tuesday, May 12th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.23). As a group, research analysts predict that Damora Therapeutics, Inc. Common Stock will post -0.95 EPS for the current fiscal year.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.